About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Melanoma Clinical Trials in Tennessee | 340 Studies

Clinical Trials MelanomaTennessee

Melanoma Clinical Trials in Tennessee

Find 340 clinical trials for melanoma near Tennessee. Connect with research centers in your area.

All Melanoma trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 41-60 of 340 trials

CompletedSingle-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene LaherparepvecThe primary objective was to estimate the proportion of participants with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after…NCT02014441·Tampa, Florida and 13 others Active not recruitingA Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with…NCT05933577·Springdale, Arkansas and 164 others

Melanoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedA Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant MelanomaThis multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF…NCT01667419·Birmingham, Alabama and 206 others

CompletedErlotinib and Bevacizumab in Treating Patients With Stage IV MelanomaRATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.NCT00466687·Nashville, Tennessee and 3 others

CompletedA Study of GSK2118436 in BRAF Mutant Metastatic MelanomaBRF113710 is a Phase II, single-arm, open-label study to assess the efficacy, safety, and tolerability of GSK2118436 administered twice daily as a single agent in subjects with…NCT01153763·Los Angeles, California and 22 others

CompletedA Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesThis is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and…NCT04772989·Los Angeles, California and 21 others

RecruitingA Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or…NCT04913285·Los Angeles, California and 47 others

TerminatedRTX-224 Monotherapy in Patients With Solid TumorsThis is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid…NCT05219578·Scottsdale, Arizona and 4 others

CompletedA Study of INCAGN01876 in Participants With Advanced or Metastatic Solid TumorsThis was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts.NCT02697591·Los Angeles, California and 7 others

TerminatedA Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced MelanomaThe purpose of this study was to evaluate safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib)…NCT02967692·Encinitas, California and 178 others

CompletedSU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaThe purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region.NCT00577382·Boston, Massachusetts and 4 others

Active not recruitingADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.NCT04044859·Orlando, Florida and 16 others

CompletedFirst Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursThe purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination…NCT04504669·Baltimore, Maryland and 12 others

CompletedCabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid TumorsThis phase I trial studies the side effects and best dose of cabozantinib S-malate in treating younger patients with solid tumors that have come back or no longer respond to…NCT01709435·Birmingham, Alabama and 22 others

TerminatedA Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTo characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.NCT02974725·San Diego, California and 31 others

CompletedSRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)This was a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK)…NCT04291079·Fullerton, California and 21 others

CompletedPH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaThe purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral…NCT01621490·Los Angeles, California and 13 others

RecruitingPilot Study of Bone Mineral Density Changes During Anti-PD-1 ImmunotherapyImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and…NCT07555210·Nashville, Tennessee

TerminatedFT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsThis is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.NCT05069935·Hackensack, New Jersey and 3 others

Enrolling by invitationA Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentThis study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab.NCT06848088·Los Angeles, California and 10 others

PreviousPage 3 of 17Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Leukemia Lymphoma